Trade Biodesix, Inc. - BDSX CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.72
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.02154 %(-$4.31)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.02154%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.000682 %(-$0.14)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.00068%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 100
• Margin: 5.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.02154 %
  (-$4.31)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.000682 %
  (-$0.14)

Key Stats

• Prev. Close: 23.83
• Open: 24.51
• 1-Year Change: 5963.83%
• Day's Range: 24.04 - 24.91

Trade Biodesix, Inc. - BDSX

About Biodesix Inc

Biodesix, Inc. is a United States-based company engaged in developing and commercializing blood-based diagnostic tests for oncology. The Company’s product Biodesix Lung Reflex integrates genomic and proteomic blood-based results to reveal both sides of lung cancer. Its GeneStrat test offers blood-based mutation results within 72 hours for patients with non-small cell lung cancer (NSCLC). Its VeriStrat testing provides blood-based predictive and prognostic proteomic information with (NSCLC) who test negative for estimated glomerular filtration rate (EGFR) mutations (EGFR wild-type) or whose EGFR mutation status is unknown.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Biodesix Inc revenues increased 20% to $54.5M. Net loss increased 38% to $43.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Sales, marketing, general and administ increase of 49% to $43.6M (expense), Research and development - Balancing v increase of 19% to $12.2M (expense).